04:23 PM EDT, 06/13/2024 (MT Newswires) -- Matthew L. Posard, Director, on June 11, 2024, sold 20,000 shares in Halozyme Therapeutics ( HALO ) for $1,006,300. Following the Form 4 filing with the SEC, Posard has control over a total of 99,755 shares of the company, with 99,755 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1159036/000141588924016672/xslF345X03/form4-06132024_080638.xml